Power3 Named a ‘Top Company in Cancer and CNS Biomarkers’

THE WOODLANDS, Texas -- Power3 Medical Products, Inc. (OTCBB:PWRM), has been cited by Espicom Business Intelligence Market Report as a “top company” in its new “Cancer, CNS, and Cardiovascular Biomarkers, Players, Products and Prospects” report.

Espicom is a leading provider of independent and impartial market information, with more than 25 years of experience in the medical devices and pharmaceuticals markets.

“There are huge markets and opportunities for biomarkers and tests to diagnose devastating diseases,” said Dr. Ira L. Goldknopf, president and chief scientific officer of Power3. “Power3 is honored to be recognized by such a prestigious independent global organization as Espicom,” he said. “It is very encouraging when a major analyst group knows your work, follows your progress, and singles you out for your efforts.

“Power3,” he said, “sincerely thanks Espicom for this recognition, and does so with a pledge to continue to advance our efforts in cancer and CNS as well as pursue our cardiovascular program, where we have had encouraging results with Metabolic Syndrome.”

Helen Park, the interim CEO of Power3, said the recognition by Espicom came at a time when the company “is taking steps to finalize several agreements and complete clinical trials for CNS diseases, including Alzheimer’s and Parkinson’s, and for breast cancer.

“This recognition is important for health care overall, and is very good news for our shareholders,” she said. “It has taken many years of hard work by our entire staff at Power3 to reach this status, as we continue to strive toward our goals, especially in the unmet needs arena, with these and other diagnostic tests.”

Source: Power3 Medical Products, Inc.